Dianthus Therapeutics Inc
Research Dianthus Therapeutics Inc (DNTH) on Bullrun: market cap USD 6.14B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDNTH
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 6.14B
- Financial periodQ2 2026
- RevenueUSD 761.00K
- Net income-USD 50.22M
- Free cash flow-USD 49.16M
Valuation Snapshot
latest market cap is USD 6.14B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.04M | -USD 162.34M | -USD 129.27M | n/a | -4.2 | USD 51.09M | USD 1.39M | USD 493.40M |
| FY2024 | USD 6.24M | -USD 84.97M | -USD 78.29M | n/a | -2.55 | USD 22.79M | USD 1.49M | USD 352.48M |
| FY2023 | USD 2.83M | -USD 43.55M | -USD 37.20M | n/a | -8.45 | USD 132.33M | USD 585.00K | USD 168.87M |
| FY2022 | USD 6.42M | -USD 28.48M | -USD 29.38M | n/a | -32.57 | USD 15.37M | USD 788.00K | -USD 44.37M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 6.14B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.78B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 678.31M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 154.10M | n/a | n/a | n/a |
About Dianthus Therapeutics Inc
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Dianthus Therapeutics Inc's market cap?
Dianthus Therapeutics Inc's market capitalization is USD 6.14B.
What does Dianthus Therapeutics Inc do?
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc.